Reversal of Immunogenicity in Pediatric Inflammatory Bowel Disease Patients Receiving Anti-Tumor Necrosis Factor Medications

Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immun...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pediatr Gastroenterol Hepatol Nutr
Autors principals: Kang, Elise, Khalili, Ali, Splawski, Judy, Sferra, Thomas J., Moses, Jonathan
Format: Artigo
Idioma:Inglês
Publicat: The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6182480/
https://ncbi.nlm.nih.gov/pubmed/30345247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5223/pghn.2018.21.4.329
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars